세포 기반 분석 및 HCS(High Content Screening) 시장 : 사용자별, 제품별 예측 - 경영 임원용 및 컨설턴트용 가이드 첨부(2026-2030년)

Report Overview:

Cell Based Assays are a mainstay of drug development and scientific research, and now research activity is growing strongly. On top of this new technology is allowing Cell Based Assays to be used to measure any aspect of cell function. This market just keeps on growing with no end in sight. The workhorse of the pharmaceutical industry is becoming a central player in biotechnology.

Cell-based assays represent a foundational technology within life sciences research, drug discovery, and biotechnology development. These assays use living cells to evaluate biological responses to chemical compounds, biologics, genetic modifications, or environmental stimuli. By measuring cellular processes such as proliferation, apoptosis, receptor activation, gene expression, and metabolic activity, cell-based assays provide physiologically relevant insights that are critical for understanding disease mechanisms and developing new therapeutic products.

The global Cell-Based Assay market is estimated to exceed approximately USD 18-25 billion annually and is projected to grow at compound annual growth rates of approximately 8-11% over the next decade. Growth is driven by increasing pharmaceutical research and development activity, expansion of biologics pipelines, advances in cell culture technologies, and increasing use of high-throughput screening platforms. Demand for more predictive experimental models is also supporting increased adoption of advanced cell-based assay systems.

Cell-based assays are widely used across pharmaceutical, biotechnology, academic, and contract research organizations to evaluate drug efficacy, toxicity, and mechanism of action. These assays provide more biologically relevant information compared with biochemical assays that evaluate isolated molecular targets. Increasing emphasis on precision medicine and targeted therapeutics is further expanding demand for functional cellular testing platforms capable of evaluating complex biological responses.

Role in Drug Discovery and Biomedical Research

Cell-based assays play a central role in drug discovery workflows by enabling researchers to evaluate how candidate compounds interact with biological systems. Early-stage screening programs often rely on cell-based assays to identify compounds with desired biological activity.

Functional assays are used to evaluate potency, selectivity, and toxicity of candidate drug compounds. Cell-based toxicity assays can help identify compounds with unfavorable safety profiles before entering clinical development.

Cancer research relies heavily on cell-based assays to evaluate responses of tumor cells to therapeutic agents. Immunology research uses cell-based assays to evaluate immune cell activation, cytokine production, and signaling pathway activity.

Neuroscience research uses cell-based assays to study neuronal signaling and neurodegenerative disease mechanisms.

Stem cell research relies on cell-based assays to study cellular differentiation and tissue development.

Cell-based assays are also widely used in infectious disease research to evaluate host-pathogen interactions.

Biotechnology companies use cell-based assays to evaluate biological activity of monoclonal antibodies and other biologic drugs.

Technology Platforms

Cell-based assays incorporate a range of technology platforms designed to measure biological responses within living cells.

Reporter gene assays use genetically engineered cells to produce measurable signals such as luminescence or fluorescence in response to activation of specific biological pathways.

Cell viability and proliferation assays measure effects of compounds on cell growth and survival.

Signal transduction assays evaluate activation of intracellular signaling pathways.

High-content screening technologies combine automated microscopy with image analysis software to measure multiple cellular parameters simultaneously.

Flow cytometry technologies enable analysis of cell populations based on protein expression and cell surface markers.

3D cell culture systems provide more physiologically relevant models compared with traditional two-dimensional cell cultures.

Organoid technologies enable study of tissue-like structures derived from stem cells.

Microfluidics and organ-on-chip systems simulate physiological environments and cell-cell interactions.

Automation technologies improve reproducibility and enable high-throughput screening workflows.

Market Drivers

Several factors are driving growth in the cell-based assay market.

Expansion of pharmaceutical pipelines is increasing demand for predictive preclinical testing tools.

Growth in biologics and gene therapy development is increasing demand for functional cellular assays.

Advances in cell culture technologies are improving biological relevance of experimental models.

Increased adoption of high-throughput screening technologies is supporting demand for assay kits and reagents.

Increasing use of precision medicine approaches is driving demand for assays capable of evaluating complex biological responses.

Growth in academic research funding supports adoption of advanced assay technologies.

Increasing regulatory emphasis on demonstrating biological activity of therapeutic products supports use of validated cell-based assays.

Expansion of contract research organizations supports demand for assay services.

Advances in imaging technologies enable measurement of complex cellular phenotypes.

Market Segmentation

The cell-based assay market can be segmented by product type, end user, and geographic region.

By product type, reagents and assay kits represent a significant portion of market revenue due to recurring demand.

End users include pharmaceutical companies, biotechnology companies, academic research institutions, and contract research organizations.

North America represents a major regional market due to strong pharmaceutical research activity and biotechnology innovation.

Europe represents a significant market supported by academic research institutions and pharmaceutical companies.

Asia-Pacific markets are expanding due to increasing investment in life sciences research and drug development capabilities.

Government funding for biomedical research supports demand for cell-based assay technologies.

Competitive Landscape

The cell-based assay market includes reagent suppliers, cell line providers, assay kit manufacturers, instrument developers, and contract research organizations.

Competition is influenced by assay reliability, reproducibility, ease of use, and compatibility with automation platforms.

Companies are increasingly developing integrated solutions combining reagents, cell lines, detection instruments, and data analysis software.

Strategic partnerships between reagent suppliers and pharmaceutical companies are common.

Intellectual property related to cell lines and assay technologies may influence competitive positioning.

Companies are investing in development of advanced cellular models that better replicate human physiology.

High-content screening technologies represent an important area of innovation.

Integration of assay technologies with data analytics tools may provide competitive advantages.

Future Outlook

The cell-based assay market is expected to continue expanding as pharmaceutical research increasingly relies on biologically relevant experimental models.

Advances in 3D cell culture and organoid technologies may improve predictive accuracy of preclinical studies.

Automation of laboratory workflows may improve reproducibility and reduce cost per experiment.

Artificial intelligence tools may improve analysis of complex cellular datasets.

Integration of multi-omics technologies with cell-based assays may improve understanding of disease mechanisms.

Expansion of gene therapy and cell therapy pipelines may increase demand for functional cellular assays.

Overall, cell-based assays represent essential tools supporting drug discovery and biomedical research. Continued advances in cell biology technologies, automation platforms, and data analytics are expected to support sustained market growth.

Table of Contents

1 Market Guides

• 1.1 Situation Analysis
  • 1.1.1 Strategic Role in Drug Discovery and Biomedical Research
  • 1.1.2 Technological Complexity and Reproducibility Challenges
  • 1.1.3 Cost Structure and Workflow Efficiency
  • 1.1.4 Adoption of 3D Cell Culture and Advanced Models
  • 1.1.5 Integration with High-Throughput Screening Technologies
  • 1.1.6 Regulatory Expectations in Biopharmaceutical Development
  • 1.1.7 Competitive Landscape and Industry Structure
  • 1.1.8 Data Analysis and Interpretation Challenges
  • 1.1.9 Geographic Market Dynamics
  • 1.1.10 Outlook and Strategic Implications
• 1.2 Guide for Executives and Marketing Staff
• 1.3 Guide for Investment Analysts and Management Consultants
  • 1.3.1 Impact of Artificial Intelligence

2 Introduction and Market Definition

• 2.1 What are Cell Based Assays?
• 2.2 Clinical Trial Failures
  • 2.2.1 Immuno-oncology Plays a Leading Role in Cell Based Assays
• 2.3 Infectious Disease Will Play a Larger Role
• 2.4 Market Definition
  • 2.4.1 Market Size
  • 2.4.2 Currency
  • 2.4.3 Years
• 2.5 Methodology
  • 2.5.1 Methodology
  • 2.5.2 Sources
  • 2.5.3 Authors
• 2.6 U.S. Medical Market and Pharmceutical Research Spending - Perspective
  • 1.5.1 U.S. Expenditures for Pharmaceutical Research

3 Cell Based Assays - Guide to Technology

• 3.1 Cell Cultures
  • 3.1.1 Cell Lines
  • 3.1.2 Primary Cells
  • 3.1.3 Stem Cells
  • 3.1.4 iPSC's - The Special Case
• 3.2 Cell Assays
• 3.3 Cell Viability Assays
• 3.4 Cell Proliferation Assays
• 3.5 Cytotoxicity Assays
• 3.6 Cell Senescence Assays
• 3.7 Apoptosis
• 3.8 Autophagy
• 3.9 Necrosis
• 3.10 Oxidative Stress
• 3.11 2D vs. 3D
• 3.12 Signalling Pathways, GPCR
• 3.13 Immune Regulation & Inhibition
• 3.14 Reporter Gene Technology
• 3.15 CBA Design & Development
• 3.16 Cell Based Assays - The Takeaway

4 Industry Overview

• 4.1 Players in a Dynamic Market
  • 4.1.1 Academic Research Lab
  • 4.1.2 Contract Research Organization
  • 4.1.3 Genomic Instrumentation Supplier
  • 4.1.4 Cell Separation and Viewing Supplier
  • 4.1.5 Cell Line and Reagent Supplier
  • 4.1.6 Pharmaceutical Company
  • 4.1.7 Audit Body
  • 4.1.8 Certification Body

5 Market Trends

• 5.1 Factors Driving Growth
  • 5.1.1 Candidate Growth
  • 5.1.2 Immuno-oncology
  • 5.1.3 Genomic Blizzard
  • 5.1.4 Technology Convergence
  • 5.1.5 The Insurance Effect
• 5.2 Factors Limiting Growth
  • 5.2.1 CBA Development Challenges
  • 5.2.2 Instrument Integration
  • 5.2.3 Protocols
• 5.3 Technology Development
  • 5.3.1 3D Assays
  • 5.3.2 Automation
  • 5.3.3 Software
  • 5.3.4 Primary Cells
  • 5.3.5 Signalling and Reporter Genes
  • 5.3.6 The Next Five Years

6 Cell Based Assays Recent Developments

• 6.1 Recent Developments
  • 6.1.1 Importance of These Developments
  • 6.1.2 How to Use This Section
• 6.2 New cell-based Screening Panel
• 6.3 New platform will accelerate single-cell analysis workflow
• 6.4 CytoTronics Announces Pixel Octo
• 6.5 Cell Painting boosts high-throughput screening
• 6.6 Castle Biosciences Sees Big Gains in New Testing Niches
• 6.7 Cell-Based Assay Outperforms Others
• 6.8 3D spheroid model Monitors T-cell invasion
• 6.9 BioAuxilium Launches New Biomarker Assay
• 6.10 Charles River Laboratories Acquires SAMDI Tech
• 6.11 Axion BioSystems Launches New High-Throughput Live-Cell Imaging Platform
• 6.12 Fujifilm's Life Sciences Invests in PhenoVista Biosciences
• 6.13 Nucleai Launches New Multiplex Imaging Spatial Analysis Solution
• 6.14 BIO-TECHNE ANNOUNCES MULTI-OMIC RNASCOPE ASSAYS
• 6.15 Indivumed, CellPhenomics Partner on Cancer Drug Target Research
• 6.16 Synthego to Accelerate Drug Discovery
• 6.17 Long COVID Detected By Cell-Based Assay
• 6.18 Nanolive closes a USD 20 million Funding Round
• 6.19 Depixus Seeks to Commercialize 'Magnetic Tweezers' for Drug Discovery
• 6.20 BioAuxilium Research Expands its Cell Signaling Assay Portfolio
• 6.21 Droplet Genomics Debuts New Microfluidic Screening Platform
• 6.22 DLP Plus Single-Cell Sequencing Method Spreads From Canada to Cancer Labs Worldwide
• 6.23 Secondcell Bio to Make Creation of Cell Lines Easy
• 6.24 Nanolitre-scale cell assays developed with droplet microarraymass spec
• 6.25 Thermo Fisher Scientific Acquires Cell Sorting Technology
• 6.26 Cellink to Distribute Phasefocus High-Content Cell Imaging Platform
• 6.27 Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance
• 6.28 Cancer Genetics to Acquire Organoid Startup Stemonix
• 6.29 Curi Bio Acquires Artificial Intelligence Firm Dana Solutions
• 6.30 CRISPR Screens Uncover Novel Cancer Therapy Targets
• 6.31 ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam

7 Profiles of Key Cell Based Assay Companies

• 7.1 Abcam
• 7.2 Agilent
• 7.3 Aurora Biomed
• 7.4 Axxam
• 7.5 Beckman Coulter Diagnostics
• 7.6 Becton, Dickinson and Company
• 7.7 Berkley Lights
• 7.8 BioIVT
• 7.9 Bio-Rad Laboratories, Inc.
• 7.10 BMG Labtech
• 7.11 Bruker
• 7.12 Cell Biolabs, Inc.
• 7.13 Cell Signaling Technology, Inc.
• 7.14 Charles River Laboratories
• 7.15 Corning, Inc.
• 7.16 Cytek Biosciences
• 7.17 Cytovale
• 7.18 Deepcell
• 7.19 Enzo Biochem
• 7.20 Eurofins DiscoverX Corporation
• 7.21 Evotec AG
• 7.22 Excellerate Bioscience
• 7.23 Fujifilm Cellular Dynamics International
• 7.24 Genedata
• 7.25 Hemogenix
• 7.26 Invivogen
• 7.27 Leica Biosystems
• 7.28 Lonza Group Ltd.
• 7.29 Luminex Corp (DiaSorin)
• 7.30 Merck & Co., Inc
• 7.31 Miltenyi Biotec
• 7.32 Molecular Devices
• 7.33 Nanion
• 7.34 Ncardia
• 7.35 New England Biolabs, Inc.
• 7.36 Novogene Bioinformatics Technology Co., Ltd.
• 7.37 Olympus
• 7.38 Origene Technologies
• 7.39 Promega
• 7.40 Qiagen
• 7.41 Reaction Biology
• 7.42 Recursion Pharma
• 7.43 Revvity
• 7.44 Roche Diagnostics
• 7.45 Sartorius
• 7.46 Sartorius-ForteBio
• 7.47 Sartorius-IntelliCyt
• 7.48 Singleron Biotechnologies
• 7.49 Sony Biotechnology
• 7.50 SPT Labtech
• 7.51 Stemcells Technologies Canada Inc.
• 7.52 Tecan
• 7.53 Thermo Fisher Scientific Inc.
• 7.54 Vitro Biopharma

8 Global Market Size

• 8.1 Global Market Overview by Country
  • 8.1.1 Table - Global Market by Country
  • 8.1.2 Chart - Global Market by Country
• 8.2 Global Market by User - Overview
  • 8.2.1 Table - Global Market by User
  • 8.2.2 Chart - Global Market by User - Base/End Year Comparison
  • 8.2.3 Chart - Global Market by User - Base Year
  • 8.2.4 Chart - Global Market by User - End Year
  • 8.2.5 Chart - Global Market by User - Share by Year
• 8.3 Global Market by Product Class - Overview
  • 8.3.1 Table - Global Market by Product Class
  • 8.3.2 Chart - Global Market by Product Class - Base/End Year Comparison
  • 8.3.3 Chart - Global Market by Product Class - Base Year
  • 8.3.4 Chart - Global Market by Product Class - End Year
  • 8.3.5 Chart - Global Market by Product Class - Share by Year

9 Global Market by User Type

• 9.1 Pharma
  • 9.1.1 Table Pharma - by Country
  • 9.1.2 Chart - Pharma Growth
• 9.2 Research
  • 9.2.1 Table Research - by Country
  • 9.2.2 Chart - Research Growth
• 9.3 Industry/Cosmetic
  • 9.3.1 Table Industry/Cosmetic - by Country
  • 9.3.2 Chart - Industry/Cosmetic Growth

10 Cell Based Assay by Product Class

• 10.1 Instrument
  • 10.1.1 Table Instrument - by Country
  • 10.1.2 Chart - Instrument Growth
• 10.2 Reagent
  • 10.2.1 Table Reagent - by Country
  • 10.2.2 Chart - Reagent Growth
• 10.3 Services
  • 10.3.1 Table Services - by Country
  • 10.3.2 Chart - Services Growth
• 10.4 Software
  • 10.4.1 Table Software - by Country
  • 10.4.2 Chart - Software Growth

11 Appendices

• 11.1 FDA Cancer Drug Approvals by Year
• 11.2 Clinical Trials Started
• 11.3 Share of Pharma R&D by Country

Table of Tables

• Table 1 The Large Variety of Cell Lines
• Table 2 Some Common Viability Assays
• Table 3 Oxidative Stress Related Diseases
• Table 4 Important Signalling Pathways
• Table 5 Market Players by Type
• Table 6 Five Factors Driving Growth
• Table 7 Three Factors Limiting Growth
• Table 8 - Global Market by Region
• Table 9 Global Market by User
• Table 10 Global Market by Product Class
• Table 11 Pharma by Country
• Table 12 Research by Country
• Table 13 Industry/Cosmetic by Country
• Table 14 Instrument by Country
• Table 15 Reagent by Country
• Table 16 Services by Country
• Table 17 Software by Country

Table of Figures

• Figure 1 Reasons for clinical Failure by Phase
• Figure 2 Immunotherapy Clinical Trial Growth
• Figure 3 Pharmaceutical Research Expenditures ($Billion)
• Figure 4 Oxidative Stress and Free Radical Toxicity
• Figure 5 FDA Cancer Drug Approvals
• Figure 6 The Changing Approach to Cancer Diagnostics
• Figure 7 Growth rates of Cell Based Assays by Product Class
• Figure 8 Global Market Share Chart
• Figure 9 Global Market by User - Base vs. End Year
• Figure 10 Global Market by User Base Year
• Figure 11 Global Market by User End Year
• Figure 12 User Share by Year
• Figure 13 Global Market by Product Class - Base vs. End Year
• Figure 14 Global Market by Product Class Base Year
• Figure 15 Global Market by Product Class End Year
• Figure 16 Product Class Share by Year
• Figure 17 Pharma Growth
• Figure 18 Research Growth
• Figure 19 Industry/Cosmetic Growth
• Figure 20 Instrument Growth
• Figure 21 Reagent Growth
• Figure 22 Services Growth
• Figure 23 Software Growth
• Figure 24 FDA Cancer Drug Approvals by Year
• Figure 25 Clinical Trials for Immunotherapy by Year
• Figure 26 Share of Pharma R&D by Country